Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin‐Like Receptors (KIR) Types on Heparin‐Induced Thrombocytopenia (HIT)

Heparin‐induced thrombocytopenia (HIT) is an unpredictable, life‐threatening, immune‐mediated reaction to heparin. Variation in human leukocyte antigen (HLA) genes is now used to prevent immune‐mediated adverse drug reactions. Combinations of HLA alleles and killer cell immunoglobulin‐like receptors (KIR) are associated with multiple autoimmune diseases and infections. The objective of this study is to evaluate the association of HLA alleles and KIR types, alone or in the presence of different HLA ligands, with HIT. HIT cases and heparin‐exposed controls were identified in BioVU, an electronic health record coupled to a DNA biobank. HLA sequencing and KIR type imputation using Illumina OMNI‐Quad data were performed. Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity. Analysis was restricted to KIR types and HLA alleles with a frequency greater than 0.01. The p values for HLA and KIR association were corrected by using a false discovery rate q<0.05 and HLA*KIR interactions were considered significant at p<0.05. Sixty‐five HIT cases and 350 matched controls were identified. No statistical differences in baseline characteristics were observed between cases and controls. The HLA‐DRB3*01:01 allele was significantly associated with HIT in the overall population (odds ratio 2.81 [1.57–5.02], p=2.1×10−4, q=0.02) and in individuals with European ancestry, independent of other alleles. No KIR types were associated with HIT, although a significant interaction was observed between KIR2DS5 and the HLA‐C1 KIR binding group (p=0.03). The HLA‐DRB3*01:01 allele was identified as a potential risk factor for HIT. This class II HLA gene and allele represent biologically plausible candidates for influencing HIT pathogenesis. We found limited evidence of the role of KIR types in HIT pathogenesis. Replication and further study of the HLA‐DRB3*01:01 association is necessary.

[1]  G. Arepally,et al.  Immune pathogenesis of heparin-induced thrombocytopenia , 2016, Thrombosis and Haemostasis.

[2]  P. Bierling,et al.  Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage , 2016, Transfusion.

[3]  Katherine K. Matthews,et al.  Activation‐Induced Killer Cell Immunoglobulin‐like Receptor 3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis , 2015, Arthritis & rheumatology.

[4]  Gil McVean,et al.  Imputation of KIR Types from SNP Variation Data , 2015, American journal of human genetics.

[5]  D. Roden,et al.  A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record , 2014, Thrombosis and Haemostasis.

[6]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[7]  Xiangsheng Chen,et al.  Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. , 2013, The Journal of investigative dermatology.

[8]  H. Watson,et al.  Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition , 2012, British journal of haematology.

[9]  G. Arepally,et al.  Critical role for mouse marginal zone B cells in PF4/heparin antibody production. , 2012, Blood.

[10]  Adam Cuker,et al.  Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. , 2012, Blood.

[11]  A. Dans,et al.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[12]  Dana C Crawford,et al.  Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality , 2011, Genetic epidemiology.

[13]  T. Ittermann,et al.  Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. , 2011, Blood.

[14]  D. Podzamczer,et al.  Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent , 2011, AIDS.

[15]  A. Cuker.  Heparin-induced thrombocytopenia: present and future , 2011, Journal of Thrombosis and Thrombolysis.

[16]  G. Guyatt,et al.  The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. , 2010, Journal of critical care.

[17]  M. Scully,et al.  Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link , 2010, Journal of thrombosis and haemostasis : JTH.

[18]  Randolph A. Miller,et al.  Research Paper: Evaluation of a Method to Identify and Categorize Section Headers in Clinical Documents , 2009, J. Am. Medical Informatics Assoc..

[19]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[20]  Randolph A. Miller,et al.  Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor , 2009, Int. J. Medical Informatics.

[21]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[22]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[23]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[24]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[25]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[26]  P. Wells,et al.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.

[27]  M. Franchini.  Heparin-induced thrombocytopenia: an update , 2005, Thrombosis journal.

[28]  T. Kohlmann,et al.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis , 2005, Thrombosis and Haemostasis.

[29]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[31]  R. Bertina,et al.  Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues , 2004, Journal of thrombosis and haemostasis : JTH.

[32]  P. Prandoni,et al.  The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. , 2003, Blood.

[33]  N. Heddle,et al.  Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.

[34]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[35]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[36]  M. Ernst,et al.  The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. , 2000, Blood.

[37]  W D Flanders,et al.  Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! , 1996, American journal of epidemiology.

[38]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[39]  C. Kaplan,et al.  HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. , 1990, Human immunology.

[40]  R. Díaz-Peña,et al.  Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn's disease. , 2016, Human immunology.

[41]  T. Fiore,et al.  Anti-heparin-platelet factor 4 antibodies after cardiopulmonary bypass: role of HLA expression. , 2001, Haematologica.